Transforming Drug Discovery and Future Growth of Organ On A Chip Market Sees Promising Growth in 2024 -2031, Size, Share | Nortis, TissUse, Tara Biosystems, and AxoSim

Market Overview:

Organ on a chip is a microfluidic cell culture platform containing living cells on chips and organs that mimic organ- and body-level functions and physiological responses. These chips make it possible to culture, stimulate and analyse live cells and tissues outside a living body.

Market Dynamics:

The organ on a chip market is expected to witness a significant growth over the forecast period owing to growing application of organ chips in drug development and testing. Organ chips help in testing drugs in a more realistic and predictive human disease model. They reduce the use of animal models in early stage drug development by providing human-relevant data. For instance, according to World Health Organization (WHO), around 80% of drug candidates fail in clinical trials due to lack of efficacy or unpredicted side effects in human. Organ chips aid in identifying such issues in early stages of drug development thus reducing costs associated with drug failure in later stages. Moreover, increasing R&D investments by pharmaceutical companies to develop effective drugs is also expected to augment the market growth over the forecast period.

Get an Exclusive Sample Copy of the Report at: - https://www.coherentmarketinsights.com/insight/request-sample/49

Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, a detailed analysis of the competitive landscape, and product services of key players. Analysis of Organ On A Chip companies, key tactics followed by Leading Key Players:

◘ Organovo
◘ Hepregen
◘ Hurel Corporation
◘ Nortis
◘ TissUse
◘ Tara Biosystems
◘ AxoSim

Increasing research and development activities focused on developing organ chips

The organ on a chip market has seen substantial growth in research and development activities aimed at developing advanced organ chip models that can better mimic key aspects of human physiology. Major pharmaceutical companies are investing heavily in organ chip technology R&D as they recognize the potential of chips to replace animal models and accelerate drug development. Organ chips allow complex multi-organ interactions to be studied at a low cost compared to animal and human clinical trials. The National Institutes of Health has also provided significant funding for organ chip research through various initiatives like the Organ Chip Program. Several startups have also been created with the goal of commercializing organ chips. The increasing focus on R&D and new product development by both public and private players is a major driver expected to support ongoing market growth.

Growing demand to adopt alternative methods for drug screening and toxicity testing

Traditional drug development methods relying on animal models and human clinical trials are costly, time-consuming, and raise ethical concerns. There is a growing need within the pharmaceutical industry and regulatory agencies to adopt alternative approaches like organ-on-chip technology that can offer more predictive testing of drug candidates. Organ chips recreate key aspects of human physiology in a microfluidic chip format and allow drugs to be tested on living, functional human tissues. This helps address many of the translational challenges associated with animal models. Organ chips also enable multi-organ interactions and disease modeling to be studied earlier in the drug development process. The potential of organ chips to serve as an alternative to animal testing and help reduce late-stage drug candidate attrition is a key factor driving increased commercial adoption of the technology.

Limited standardization impacting wider adoption

While organ chip technology offers great promise, a major challenge limiting its wider commercialization is the lack of standardization. Different research groups have developed organ chips using diverse fabrication techniques and modeling different organs. This makes performance comparison difficult and hinders regulatory acceptance. There is also no standardization in how experiments are conducted or data is reported from organ chips. Widespread clinical translation will require development of reference organ chip models and standardized protocols for their characterization, operation, and validation. Establishing performance qualification criteria is also important for regulatory approval and commercialization. The current lack of standardization adds complexity and reduces adoption potential for some applications. Concerted efforts are needed to develop standards to help address this key market restraint.

Buy This Premium Report and Get Upto 25 % OFF: https://www.coherentmarketinsights.com/insight/buy-now/49

Opportunities in disease modeling and personalized medicine testing

As organ chip technology advances, it is increasingly being utilized for modeling human diseases and for personalized testing applications. Disease modeling organ chips that recreate the physiology of diseased organs can help enhance understanding of pathophysiology and identify new drug targets. They can also serve as platforms for precision medicine by facilitating personalized drug screening and toxicity testing using a patient's own cells. This reduces reliance on population level studies. The ability of organ chips to work with small amounts of living human cells or tissues obtained from biopsies or stem cells opens up opportunities in cell-based screening for cancer diagnostics, antimicrobial susceptibility testing, and personalized drug therapy development. The growing push for personalized healthcare is expected to boost adoption of organ chip approaches.

Market trends towards developing multi-organ chip systems

A major trend in the organ on chip market is the focus on developing advanced multi-organ chip platforms that can model complex interactions between two or more organ systems. Traditional single organ chips only provide limited physiological insight. Consortia like the United States National Center for Advancing Translational Sciences are funding several projects to integrate different organ chip models on a single microfluidic chip to better emulate human physiology. Commercial players are also releasing co-culture organ chip platforms. The trend reflects a recognition that whole-body responses emerge from complex inter-organ communication which needs to be captured for clinically predictive testing. As multi-organ integration capabilities improve through ongoing R&D, the demand for organ chips mimicking human organ network behavior more closely is expected to increase significantly over the coming years.

The Study Objectives are:

A comprehensive insight into key players operating in the Organ On A Chip Market and their corresponding data.
It includes product portfolio, annual revenue, expenditure on research and development, geographical presence, key developments in recent years, and growth strategies.
Regional analysis, which includes insight into the dominant market and corresponding market share.
It also includes various socio-economic factors affecting the evolution of the market in the region.
The report offers a comprehensive insight into different individuals from value chains such as raw materials suppliers, distributors, and stockholders.
Table of Contents:

Market scenario 2024

Chapter 1: Introduction, Market Driving Force Product Objective of Study and Research Scope the Organ On A Chip market
Chapter 2: Exclusive Summary - the basic information of the Organ On A Chip Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends, and Challenges & Opportunities of the Organ On A Chip
Chapter 4: Presenting the Organ On A Chip Market Factor Analysis, Supply/Value Chain, PESTEL analysis, Market Entry, and Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User, and Region/Country 2024 - 2031
Chapter 6: Evaluating the leading manufacturers of the Organ On A Chip market which consists of its Competitive Landscape, Peer Group Analysis, Market positioning & Company Profile
Chapter 7: To evaluate the market by segments, by countries, and by Manufacturers/Companies with revenue share and sales by key countries in these various regions (2024-2031)
Chapters 8 & 9: Displaying the Appendix, Methodology, and Data Source

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/49

Key Questions Answered:

What is the market size and CAGR of the Organ On A Chip Market during the forecast period?
How is the growing demand impacting the growth of Organ On A Chip Market shares?
What is the growing demand of the Market during the forecast period?
Who are the leading vendors in the market and what are their market shares?
What is the impact of the COVID-19 pandemic on the APAC Organ On A Chip Market?

Contact Us

Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame,
CA 94010, United States
Phone: US +12067016702 / UK +4402081334027
JAPAN:+81-50-5539-1737
INDIA:+91-848-285-0837
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.